Survival following different transplant approaches.*
| . | Chronic, % . | Accelerated, % . | Blast, % . | Comments . |
|---|---|---|---|---|
| *Five-year estimates. | ||||
| Abbreviations: BMT, blood or marrow transplant; Dx, diagnosis; GVHD, graft-versus-host disease; NA, not applicable; URD, unrelated donor. | ||||
| Related | 60-80 | 40-50 | 10-20 | Age and Dx→BMT interval less important than in URD setting |
| URD | 50-80 | 20-40 | 5-20 | GVHD the biggest hurdle to success and quality of life |
| Autologous | 40-70 | NA | NA | Limited role may be resurrected in the imatinib era |
| Non-myeloablative | NA | NA | NA | Investigational |
| . | Chronic, % . | Accelerated, % . | Blast, % . | Comments . |
|---|---|---|---|---|
| *Five-year estimates. | ||||
| Abbreviations: BMT, blood or marrow transplant; Dx, diagnosis; GVHD, graft-versus-host disease; NA, not applicable; URD, unrelated donor. | ||||
| Related | 60-80 | 40-50 | 10-20 | Age and Dx→BMT interval less important than in URD setting |
| URD | 50-80 | 20-40 | 5-20 | GVHD the biggest hurdle to success and quality of life |
| Autologous | 40-70 | NA | NA | Limited role may be resurrected in the imatinib era |
| Non-myeloablative | NA | NA | NA | Investigational |